Evaluation of DILI Predictive Hypotheses in Early Drug Development

• In: Short Communications A2 on Monday, 22 May 2017, 13:30-15:00
• At: Stockholm (Sweden) (2017)
• Type: Presentation
• By: CHAN, Rosa (University of California San Francisco, Bioengineering and Therapeutic Sciences, San Francisco, United States)
• Co-author(s): Rosa Chan: Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States
  Leslie Benet: Bioengineering and Therapeutic Sciences, University of California San Francisco, San Francisco, United States
  
• Abstract:

  Backgrounds

   

  Drug-induced liver injury (DILI) is a leading cause of drug failure in clinical trials and a major reason for drug withdrawals from the market. Idiosyncratic DILI has been shown to be dependent on both daily dose and extent of hepatic metabolism. Yet, early in drug development daily dose is unknown.

  Aims

   

  Here, we

  ..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login